Acrivon Therapeutics (ACRV) announced that Adam D. Levy, Ph.D., M.B.A., has joined Acrivon as senior vice president, SVP, and head, investor relations and corporate affairs. Previously, Adam served as senior vice president of investor relations at Zentalis Pharmaceuticals (ZNTL).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACRV:
- Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Acrivon Therapeutics to Present at the Jefferies Healthcare Conference